Literature DB >> 14712083

An unexpected role for hypoxic response: oxygenation and inflammation.

Carole Peyssonaux1, Randall S Johnson.   

Abstract

The eradication of invading microorganisms depends initially on innate immunity mechanisms that preexist in all individuals and act within minutes of infection. Pathogen spread is often countered by an inflammatory response that recruits more effector molecules and cells of the innate immune system from local blood vessels, while inducing clotting farther downstream so that pathogens cannot spread throughout the blood. If a microorganism crosses an epithelial barrier and begins to replicate in the tissues of the host, it is, in some cases, immediately recognized by the mononuclear phagocytes, or macrophages, that reside in tissues. Macrophages mature continuously from circulating monocytes that leave the circulation to migrate into tissues throughout the body. The second major family of phagocytes, the neutrophils or polymorphonuclear leukocytes (PMNs) are short-lived cells that are abundant cells in the blood but are not present in healthy tissues. Both phagocytic cell types play a key role in innate immunity because they can recognize, ingest and destroy many pathogens without the aid of an adaptive immune response. This infiltration of neutrophils and later macrophages to the site of bacterial infection is tightly linked with the need of these immune defense cells to respond to the tissue microenvironment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712083

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  14 in total

1.  Metabolic requirements for neutrophil extracellular traps formation.

Authors:  Oscar Rodríguez-Espinosa; Oscar Rojas-Espinosa; María Maximina Bertha Moreno-Altamirano; Edgar Oliver López-Villegas; Francisco Javier Sánchez-García
Journal:  Immunology       Date:  2015-06       Impact factor: 7.397

Review 2.  Hypoxia and fungal pathogenesis: to air or not to air?

Authors:  Nora Grahl; Kelly M Shepardson; Dawoon Chung; Robert A Cramer
Journal:  Eukaryot Cell       Date:  2012-03-23

Review 3.  Protecting the boundary: the sentinel role of host defense peptides in the skin.

Authors:  Jamie J Bernard; Richard L Gallo
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

4.  Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression.

Authors:  Karen D Cowden Dahl; Sarah E Robertson; Valerie M Weaver; M Celeste Simon
Journal:  Mol Biol Cell       Date:  2005-02-02       Impact factor: 4.138

Review 5.  Platelet-neutrophil interactions under thromboinflammatory conditions.

Authors:  Jing Li; Kyungho Kim; Andrew Barazia; Alan Tseng; Jaehyung Cho
Journal:  Cell Mol Life Sci       Date:  2015-02-04       Impact factor: 9.261

6.  A combination of hypoxia and lipopolysaccharide activates tristetraprolin to destabilize proinflammatory mRNAs such as tumor necrosis factor-alpha.

Authors:  Christian Werno; Tobias Schmid; Steffen E Schnitzer; Kathrin Peters; Larissa Milke; Bernhard Brüne
Journal:  Am J Pathol       Date:  2010-07-16       Impact factor: 4.307

7.  Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB.

Authors:  Stilla Frede; Christian Stockmann; Patricia Freitag; Joachim Fandrey
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

Review 8.  Antimicrobial peptides, skin infections, and atopic dermatitis.

Authors:  Tissa R Hata; Richard L Gallo
Journal:  Semin Cutan Med Surg       Date:  2008-06

Review 9.  Antimicrobial peptides: natural effectors of the innate immune system.

Authors:  Katherine Radek; Richard Gallo
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 11.759

10.  Ginsenoside Rh2 Downregulates LPS-Induced NF- κ B Activation through Inhibition of TAK1 Phosphorylation in RAW 264.7 Murine Macrophage.

Authors:  Li-Hua Lian; Quan Jin; Shun-Zong Song; Yan-Ling Wu; Ting Bai; Shuang Jiang; Qian Li; Ning Yang; Ji-Xing Nan
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-17       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.